Journal of Drug Metabolism & Toxicology
Open Access

Deaa Fekri Morsi

Publications

• Research Article
  Effect of CB1-Antagonist (AM251) on Metabolic Syndrome (Prophylactic and Therapeutic)
  Author(s): Abdelbaset Taher Abdelhalim, Ahmed Mohammed Taha*, Elsayed Mohammed Tayee, Deaa Fekri Morsi, Dalia Ali GaberAbdelbaset Taher Abdelhalim, Ahmed Mohammed Taha*, Elsayed Mohammed Tayee, Deaa Fekri Morsi, Dalia Ali Gaber
  
  The present study was designed to investigate the possible prophylactic and therapeutic effect of cannabinoid receptors type1 (CB1) antagonist (AM251) on fructose-induced metabolic syndrome in rats, through administration of high fructose diet for 12 weeks. Prophylactic treatment by CB1-antagonist (AM251) significantly returned triglyceride, inflammatory, oxidative stress parameters and liver enzymes to the normal values while it significantly improved blood pressure, glucose, insulin, and IR and lipid profile but not significantly returned to the normal values. Interestingly, it significantly decreased body weight to values less than corresponding normal group. Histopathological findings confirmed that CB1-antagonist (AM251) in both prophylactic and therapeutic group improved histopathological changes of the liver and aorta induced by high fructose (60%) diet, with .. View More»
  DOI: 10.4172/2157-7609.1000236

  Abstract PDF

Relevant Topics